Nautilus Biotechnology, Inc. Deferred Costs, Noncurrent
Nautilus Biotechnology, Inc. (NAUT) had Deferred Costs, Noncurrent of $0 as of 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2022-02-24
- 2021-12-31: Deferred Costs, Noncurrent $0.00.
- 2021-09-30: Deferred Costs, Noncurrent $0.00.
- 2021-06-30: Deferred Costs, Noncurrent $0.00.
- 2020-12-31: Deferred Costs, Noncurrent $212.00K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-10 |
| 2020-12-31 | $212.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |